Mahato R I, Takemura S, Akamatsu K, Nishikawa M, Takakura Y, Hashida M
Department of Drug Delivery Research, Faculty of Pharmaceutical Sciences, Kyoto University, Japan.
Biochem Pharmacol. 1997 Mar 21;53(6):887-95. doi: 10.1016/s0006-2952(96)00880-5.
The disposition characteristics of a 20 mer antisense phosphodiester oligonucleotide (PO) and its fully phosphorothioated derivative (PS) alone or complexed with glycosylated poly(L-lysine) (galactosylated polylysine, Gal-PLL; mannosylated polylysine, Man-PLL) were studied in mice in relation to their physicochemical characteristics. Good complex formation was obtained at a ratio of 1:0.6, w/w [oligonucleotides (ODNs)/carrier]. The 1:0.6 weight ratio of ODNs/Gal-PLL and ODNs/Man-PLL complexes had zeta potentials of -27 to -31 mV and mean particle size of 100 to 160 nm. After intravenous injection, 35S-labeled ODNs were eliminated rapidly from the circulation; however, their organ disposition characteristics depended on their type. Complex formation with glycosylated PLL increased the hepatic uptake and decreased the urinary clearance of these ODNs to a great extent. These complexes were taken up by both liver parenchymal cells (PC) and nonparenchymal cells (NPC). However, ODNs/Gal-PLL complexes showed a fairly high PC concentration, whereas ODNs/Man-PLL complexes distributed equally to both PC and NPC. The hepatic uptakes of PS/Gal-PLL and PS/Man-PLL complexes were partially inhibited by prior administration of Gal-BSA and Man-BSA, respectively, suggesting their hepatic uptake via the respective receptor-mediated endocytosis. However, uptake by galactose receptors of Kupffer cells, zeta potential, particle size, and Kupffer cell phagocytosis also seem to influence their uptake process. In conclusion, this study illustrates that ODNs can be delivered to hepatocytes and macrophages via galactose and mannose receptors, respectively.
研究了一种20聚体反义磷酸二酯寡核苷酸(PO)及其完全硫代磷酸化衍生物(PS)单独或与糖基化聚(L-赖氨酸)(半乳糖基化聚赖氨酸,Gal-PLL;甘露糖基化聚赖氨酸,Man-PLL)复合后的处置特征,及其与理化性质的关系。在1:0.6(w/w)[寡核苷酸(ODN)/载体]的比例下可形成良好的复合物。ODN/Gal-PLL和ODN/Man-PLL复合物的1:0.6重量比具有-27至-31 mV的ζ电位和100至160 nm的平均粒径。静脉注射后,35S标记的ODN迅速从循环中清除;然而,它们的器官处置特征取决于其类型。与糖基化PLL复合可极大程度地增加这些ODN的肝脏摄取并降低其尿清除率。这些复合物被肝实质细胞(PC)和非实质细胞(NPC)摄取。然而,ODN/Gal-PLL复合物显示出相当高的PC浓度,而ODN/Man-PLL复合物在PC和NPC中分布均匀。PS/Gal-PLL和PS/Man-PLL复合物的肝脏摄取分别被预先给予Gal-BSA和Man-BSA部分抑制,表明它们通过各自的受体介导的内吞作用进行肝脏摄取。然而,库普弗细胞的半乳糖受体摄取、ζ电位、粒径和库普弗细胞吞噬作用似乎也影响它们的摄取过程。总之,本研究表明ODN可分别通过半乳糖和甘露糖受体递送至肝细胞和巨噬细胞。